GoBear is now part of Finder
Mylan logo

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Mylan (MYL) shares

Learn how to easily invest in Mylan shares.

Viatris Inc is a drug manufacturers-specialty & generic business based in the US. Mylan shares (MYL) are listed on the NASDAQ and all prices are listed in US Dollars. Mylan employs 35,000 staff and has a trailing 12-month revenue of around USD$11.5 billion.

How to buy shares in Mylan

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – MYL – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Compare online brokers

Name Product Number of Stocks Shares Available Markets
Interactive Brokers
Access to global markets
Yes
Global markets
Your capital is at risk.
Saxo Markets
19,000+
Yes
Global markets
Your capital is at risk.
Plus500
2,000+
No
US, UK, AU, DE, FR, IT, PT, GR, JP, SG, ZA, NL, FI, BE, DK, SE, CH, ES, AT, NO, HU, CZ, IE, PL, HK
CFD Service. Your capital is at risk.
BlackBull Markets
N/A
No
UK, HK, JP, MY, NZ, US
CFD Service. Your capital is at risk.
Libertex
50+
No
Worldwide with exception.
Except for: US/Australia/New Zealand/Belgium/British Virgin Islands/Guam/Lebanon/United States Minor/Outlying Islands/Northern Mariana Islands/Uganda/Philippines/Sri Lanka/Kuwait/South Africa/Azerbaijan/Canada/Armenia/Russia/Japan/Brasil.
CFD Service. Your capital is at risk.
Exness
N/A
No
CH, VN, TH, PH, SG, ID, IN, UAE, ZA, SA, EG, BR, CR, MX
CFD Service. Your capital is at risk.
IG
17,000+
No
DK, IE, NO, RU, DE, IT, AT, CH, ES, LU, PT, SE, FR, NL, RO, UK, US, AU, JP, SG, ZA, AE
CFD Service. Your capital is at risk.
loading

Compare up to 4 providers

Is it a good time to buy Mylan stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Mylan shares at a glance

Information last updated 2021-01-17.
52-week range$0.08 - $16.10
50-day moving average $16.42
200-day moving average $16.12
Wall St. target price$21.75
PE ratio 30.7267
Dividend yield N/A (0%)
Earnings per share (TTM) $0.52

Mylan stock price (NASDAQ: MYL)

Use our graph to track the performance of MYL stocks over time.

Is Mylan under- or over-valued?

Valuing Mylan stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Mylan's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Mylan's P/E ratio

Mylan's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 31x. In other words, Mylan shares trade at around 31x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Mylan's PEG ratio

Mylan's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.59. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Mylan's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Mylan's EBITDA

Mylan's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $3.5 billion.

The EBITDA is a measure of a Mylan's overall financial performance and is widely used to measure a its profitability.

Mylan financials

Revenue TTM $11.5 billion
Operating margin TTM 15.72%
Gross profit TTM $4.6 billion
Return on assets TTM 3.63%
Return on equity TTM 0%
Profit margin 2.31%
Book value $24.27
Market capitalisation $8.6 billion

TTM: trailing 12 months

Shorting Mylan shares

There are currently 47.1 million Mylan shares held short by investors – that's known as Mylan's "short interest". This figure is 1.4% up from 46.5 million last month.

There are a few different ways that this level of interest in shorting Mylan shares can be evaluated.

Mylan's "short interest ratio" (SIR)

Mylan's "short interest ratio" (SIR) is the quantity of Mylan shares currently shorted divided by the average quantity of Mylan shares traded daily (recently around 4.2 million). Mylan's SIR currently stands at 11.15. In other words for every 100,000 Mylan shares traded daily on the market, roughly 11150 shares are currently held short.

However Mylan's short interest can also be evaluated against the total number of Mylan shares, or, against the total number of tradable Mylan shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Mylan's short interest could be expressed as 0.09% of the outstanding shares (for every 100,000 Mylan shares in existence, roughly 90 shares are currently held short) or 0.1105% of the tradable shares (for every 100,000 tradable Mylan shares, roughly 111 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Mylan.

Mylan's environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Mylan.

When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.

Mylan's total ESG risk score

Total ESG risk: 37.23

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Mylan's overall score of 37.23 (as at 12/31/2018) is pretty weak – landing it in it in the 78th percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like Mylan is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

Mylan's environmental score

Environmental score: 1.95/100

Mylan's environmental score of 1.95 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Mylan is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

Mylan's social score

Social score: 20.21/100

Mylan's social score of 20.21 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Mylan is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

Mylan's governance score

Governance score: 14.07/100

Mylan's governance score puts it squarely in the 2nd percentile of companies rated in the same sector. That could suggest that Mylan is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

Mylan's controversy score

Controversy score: 4/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. Mylan scored a 4 out of 5 for controversy – the second-lowest score possible, reflecting that Mylan has a damaged public profile.

Mylan share dividends

We're not expecting Mylan to pay a dividend over the next 12 months.

Have Mylan's shares ever split?

Mylan's shares were split on a 3:2 basis on 8 October 2003. So if you had owned 2 shares the day before before the split, the next day you'd have owned 3 shares. This wouldn't directly have changed the overall worth of your Mylan shares – just the quantity. However, indirectly, the new 33.3% lower share price could have impacted the market appetite for Mylan shares which in turn could have impacted Mylan's share price.

Mylan share price volatility

Over the last 12 months, Mylan's shares have ranged in value from as little as $0.077 up to $16.1. A popular way to gauge a stock's volatility is its "beta".

MYL.US volatility(beta: 1.47)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Mylan's is 1.4656. This would suggest that Mylan's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Mylan overview

Mylan N. V. , together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS. The company also provides prescription products, such as EpiPen Auto-Injector; Perforomist Inhalation Solution; Dymista; Creon; and Influvac, as well as YUPELRI, an inhalation solution for the maintenance treatment of patients with chronic obstructive pulmonary diseases. In addition, it markets OTC products, including Cold-EEZE, MidNite, Vivarin, Brufen, CB12, and EndWarts. The company offers its products to therapeutic areas, such as cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, gastroenterology, immunology, infectious disease, oncology, respiratory and allergy, and women's health.

Frequently asked questions

Mylan in the news

There are no recent company news
Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More guides on Finder

Ask Finder

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked
Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy Policy and Terms.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site